一 致Ｂ：第一季度报告正文（英文版） .ppt

-14.46%,China National Accord Medicines Corporation Ltd.Stock Code:000028,200028,The First Quarterly Report for 2012Notice No.:2012-08,Short Form of the Stock:Sinopharm Accord,Accord-BChina National Accord Medicines Corporation Ltd.The First Quarterly Report 20121.Important Notes1.1 Board of Directors and the Supervisory Committee of China National Accord MedicinesCorporation Ltd.(hereinafter referred to as the Company)and its directors,supervisors and seniorexecutives hereby confirm that there are no any fictitious statements,misleading statements,orimportant omissions carried in this report,and shall take all responsibilities,individual and/or joint,for the reality,accuracy and completion of the whole contents.1.2 The First Quarterly Financial Report of 2012 has not been audited by CPAs.1.3 Mr.Wei Yulin,Chairman of the Company;Mr.Yan Zhigang,Director General Manager;Mr.Wei Pingxiao,CFO and Mr.Chi Guoguang,Financial Manager hereby confirm that the FinancialReport of the First Quarterly Report is true and complete.2.Company Profile2.1 Main accounting highlights and financial indexesUnit:RMB,At the end of thereport period,At the period-end of the last yearChanges ofBeforeAfter adjustment increase/decrease(%)adjustment,Total assets(RMB),8,069,831,512.29 7,665,759,761.04 7,680,629,146.67,5.07%,Owners,equity,attributable,to,shareholders of the listed company(RMB)Total share capital(Share),1,467,647,406.10288,149,400.00,1,350,217,871.35288,149,400.00,1,350,093,276.86288,149,400.00,8.71%0.00%,Net asset per share attributable to,shareholders of listed company,5.093,4.686,4.685,8.71%,(RMB/Share),In the report period,The same period of last yearChanges ofBeforeAfter adjustment increase/decrease(%)adjustment,Total operating income(RMB),4,274,691,013.50 3,526,818,451.42 3,534,426,881.47,20.94%,Net profit attributable to shareholders ofthe listed company(RMB),121,822,129.24,87,259,288.17,87,197,481.02,39.71%,Net cash flow arising from operatingactivities(RMB),-271,437,536.92-316,947,045.11-317,332,260.53,Net cash flow arising from operatingactivities per share(RMB/Share)Basic earnings per share(RMB/Share)Diluted earnings per share(RMB/Share)Weighted average return on equity(%),-0.9420.4230.4238.63%,-1.1000.3030.3037.96%,-1.1010.3030.3037.94%,-14.44%39.60%39.60%0.69%,Weighted average return on equity after,deducting non-recurring gains and,8.58%,7.70%,7.69%,0.89%,losses(%)Items of non-recurring gains and losses Applicable InapplicableUnit:RMB1,-,China National Accord Medicines Corporation Ltd.,The First Quarterly Report for 2012,Items of non-recurring gains and lossesGains and losses from the disposal of non-current assetsGovernmental subsidy reckoned into current gains and losses,but closely relevant to the Companys business except for thegovernmental subsidy enjoyed in quota or ration according tothe national general standardsCurrent net gains/losses of subsidiary generated fromperiod-begin to consolidation date by enterprise merger undersame controlImpairment provision reversal on account receivable whichconducting impairment testing separatelyOther non-operating income and expenditure except for theabove itemsInfluenced amount of minority shareholders equityInfluenced amount of income taxTotal,Amount fromyear-begin toperiod-end-35,049.591,284,500.28-175,050.36242,309.84199,552.20-440,050.00-268,622.84807,589.53,Remarks(Ifapplicable),2.2 Total number of shareholders at the end of the report period and shares held by the topten shareholders with unrestricted conditionsUnit:Share,Total number of shareholdersat the end of report period,18,481,Particulars about the shares held by the top ten tradable shareholders with unrestricted conditionsAmount of tradable shares with,Full name of shareholderSINOPHARM GROUP CO.,LTD.ICBCGUANGFA JUFENGSTOCK FUNDICBCHARVEST THEME NEWPOWER STOCK FUNDHTHK/CMG FSGUFP-CMG FIRSTSTATE CHINA GROWTH FDABCGREATWAL ANXINRETURN MEX STOCK FUNDICBCHARVEST STRATEGYGROWTH MIXED STOCK FUNDABCJINSHUN GREATWALLRESOURCES MONOPOLYSTOCK FUND(LOF)ICBC-GD STRATEGYSELECTED MIXED STOCKFUNDICBC UNIVERSAL BALANCEGWORTH STOCK FUNDCCBGREATWALL CONSUMERVALUE-ADDED STOCK FUND,unrestricted conditions held atthe end of report period110,459,74813,285,47710,290,2927,032,7207,000,0004,256,0424,001,4813,996,4863,721,2913,292,879,Type of sharesRMB common shareRMB common shareRMB common shareDomestically listed foreignshareRMB common shareRMB common shareRMB common shareRMB common shareRMB common shareRMB common share2,China National Accord Medicines Corporation Ltd.,The First Quarterly Report for 2012,3.Significant Events3.1 Particulars about material changes in items of main accounting statement and financialindex,and explanations of reasons,Applicable,Inapplicable,1.Account paid in advance at period-end increase 48.18 million yuan over that of period-begin withrate of 73.15 percent up.Mainly because the projects and equipment amount paid in advanceincreased from Zhijun Pharmaceutical,subsidiary of the Company;meanwhile,amount paid for goodpurchasing in advance increased due to soaring sales.2.Other account receivable at period-end increase 10.59 million yuan over that of period-begin withrate of 36.96 percent up.Mainly because acquisition of subsidiary Sinopharm Zhaoqing in this periodand amount of office establishment of Sinopharm Guangxi,subsidiary of the Company pre-paid.3.Other current assets at period-end decrease 5.16 million yuan over that of period-begin with rate of-67.44 percent up.Mainly because excess payable VAT and income tax decreased.4.Account paid in advance at period-end increase 29.61 million yuan over that of period-begin withrate of 50.44 percent up.Mainly because Zhijun Pharmaceutical,subsidiary of the Company,showsfavorable condition in aspect of sales,amount for goods received in advance increased.5.Wages payable at period-end decrease 43.8 million yuan over that of period-begin with rate of-30.75 percent up.Mainly because some of the remuneration,accrual last year,have been paid in thisperiod.6.Taxes payable at period-end increase 28.09 million yuan over that of period-begin with rate of44.17 percent up.Mainly because vary taxes growth due to soaring sales and higher profitability.7.Long-term loans at period-end increase 37.12 million yuan over that of period-begin with rate of39.88 percent up.Mainly because the new loans for Sinopharm Guangxi Logistic Park project,subsidiary of the Company,and phase II,Guanlan,Medicine R on the otherhand,financing cost increased due to financing scale enlarged.10.Loss of assets impairment has a y-o-y decrease of 5.17 million yuan with-95.92 percent up.Mainly because strictly control in inventory management and rapid up turnover of the inventory,anddepreciation provision for inventory accrued decreased.11.Non-operating income has a y-o-y decline of 0.95 million yuan with-33.57 percent up.Mainlybecause government subsidy obtained in this period decreased over same period of last year.12.Non-operating expenses have a y-o-y growth of 0.4 million yuan with 1,097.66 percent up.Mainly because external donation and losses from disposal of non-current assets show an increaseover same period of last year.13.Net profit has a y-o-y growth of 33.91 million yuan with 38.14 percent up.Mainly because salesscale enlarged,and by controlling reasonable expenses and adjusted products structure forsubordinate subsidiaries of the Company,profitability gains a more room for growth.14.Minority interest income has a y-o-y decline of 0.72 million yuan with-42.30 percent up.Mainlybecause Zhijun Wanqing,subsidiary of the Company,has a lower net profit than same period of lastyear.15.Taxes returned received have a y-o-y growth of 90,000 yuan with 116.38 percent up.Mainlybecause Zhijun Medicine Trade Company,subsidiary of the Company,has a higher export return taxthan same period of last year.16.Other cash received from operating activities have a y-o-y decline of 10.45 million yuan with-36.99 percent up.Mainly because government subsidy and other items obtained in this period have3,China National Accord Medicines Corporation Ltd.,The First Quarterly Report for 2012,lower amount than same period of last year.17.Net cash received from disposal of fixed assets,intangible assets and other long-term assets havea y-o-y decline of 0.3 million yuan with-58.85 percent up.Mainly because Zhijun Pharmaceutical,subsidiary of the Company,disposed some of the vehicle at same period of last year while no suchbusiness occurred in this period.18.Other cash received from investment activities have a y-o-y decline of 1.91 million yuan with-100 percent up.Mainly because Sinopharm Guangxi Logistic,subsidiary of the Company,obtainedsupporting grant for logistic projects from Nanning Economy Development Zone at same period oflast year while no such business occurred in this period.19.Acquisition of subsidiaries and other business units，net cash have a y-o-y growth of 5.09 millionyuan with 100 percent up.Mainly because Sinopharm Zhaoqing and Sinopharm Wuzhou wereacquired by the Company in this period whiles no such business occurred at same period of last year.20.Other cash paid for investment activities have a y-o-y decline of 9.7 million yuan with-100percent up.Mainly because Sinopharm Guangxi paid balance of business acquisition of NanningMedicine at same period of last year while no such business occurred in this period.21.Other cash received from financing activities have a y-o-y growth of 326.42 million yuan with1,732.72 percent up.Mainly because entrusted loans were increased and application of financinginstrument of supplying chains for purpose of supporting business development.22.Cash paid for debt settlement have a y-o-y growth of 108.73 million yuan with 105.60 percent up.Mainly because loans growth that debt payment correspondingly increased.23.Cash paid for dividend and profit distribution or interest settlement have a y-o-y growth of 18.36million yuan with 97.12 percent up.Mainly because financing cost increased due to financing scaleenlarged.24.Other cash paid for financing activities have a y-o-y growth of 284.62 million yuan with 869.66percent up.Mainly because entrusted loans were paid in this period and financing from supplyingchains increased over same period of last year.25.influence on cash and cash equivalent from exchange rate movement has a y-o-y decline of 2,800yuan with-1,528.95 percent up.Mainly because of the amount of foreign currency held increased.3.2 Analysis and explanation of significant events and their influence and solutions3.2.1 Particular about Qualified Opinion,Applicable,Inapplicable,3.2.2 Particular about fund offered to shareholder or its related parties by the Company andexternal guarantee with procedure violation,Applicable,Inapplicable,3.2.3 Particular about the significant contract of routine operation signed and implemented,Applicable3.2.4 OtherApplicable,InapplicableInapplicable,The Company purchased Sinopharm Wuzhou Co.,Ltd.under same control in March 2012,madeadjustment on comparison statements dated March 2011 in line with relevant regulations ofAccounting Standards for Business Enterprises No.20 Business Combination.Income fromJanuary to March for year of 2011 increased 7.69 million yuan,net profit increased-60,000 yuan andnet cash flow arising from operating activities increased-390,000 yuan while combined SinopharmWuzhou Co.,Ltd.3.3 Implementations of commitments by the Company,shareholders and actual controllerCommitments make within the report period or persisted to the period by listed company and itsdirector,supervisor and senior executives,shareholder with over 5 percent shares held and its actualcontroller,Applicable,Inapplicable,4,China National Accord Medicines Corporation Ltd.,The First Quarterly Report for 2012,3.4 Estimation of accumulative net profit from the beginning of the year to the end of nextreport period to be loss probably or the warning of its material change compared with thecorresponding period of the last year and explanation of reason,Applicable,Inapplicable,3.5 Other significant events which need explanations3.5.1 Particulars about securities investment,Applicable,Inapplicable,3.5.2 Registration form for receiving research,communication and interview in the reportperiodNo acceptation of research,communication and interview in this report period.3.6 Particulars about derivatives investment,Applicable,Inapplicable,3.6.1 Particulars about derivatives investment held at the end of report period,Applicable,Inapplicable,5,